Renal monoclonal immunoglobulin deposition disease: A report of 64 patients from a single institution

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 2, 2012, Pages 231-239

  Nasr, Samih H ^a   Valeri, Anthony M ^b   Cornell, Lynn D ^a   Fidler, Mary E ^a   Sethi, Sanjeev ^a   D'Agati, Vivette D ^b   Leung, Nelson ^a  

^a MAYO CLINIC   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN KAPPA CHAIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL INFILTRATION; CHEMOTHERAPY; CLINICAL FEATURE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE EXACERBATION; DYSPROTEINEMIA; ELECTROPHORESIS; FEMALE; FOLLOW UP; HEAVY CHAIN DISEASE; HEMATURIA; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOELECTROPHORESIS; IMMUNOGLOBULIN DEPOSITION; IMMUNOPATHOLOGY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEPHROSCLEROSIS; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEINURIA; RECURRENT DISEASE; RENAL MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOPSY; ELECTROPHORESIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEAVY CHAIN DISEASE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MINNESOTA; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PARAPROTEINEMIAS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857346852     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08640811     Document Type: Article

References (24)

1. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D'Agati VD: Renal monoclonal immunoglobulin deposition disease: The disease spectrum. J Am Soc Nephrol 12: 1482-1492, 2001
2. Denoroy L, Déret S, Aucouturier P: Overrepresentation of the V kappa IV subgroup in light chain deposition disease. Immunol Lett 42: 63-66, 1994
3. Moulin B, Deret S, Mariette X, Kourilsky O, Imai H, Dupouet L, Marcellin L, Kolb I, Aucouturier P, Brouet JC, Ronco PM, Mougenot B: Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1. J Am Soc Nephrol 10: 519-528, 1999
4. Kambham N, Markowitz GS, Appel GB, Kleiner MJ, Aucouturier P, D'agati VD: Heavy chain deposition disease: the disease spectrum. Am J Kidney Dis 33: 954-962, 1999
5. Stratta P, Gravellone L, Cena T, Rossi D, Gaidano G, Fenoglio R, Lazzarich E, Quaglia M, Airoldi A, Bozzola C, Monga G, Valente G, Canavese C, Magnani C: Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: A single center experience. Crit Rev Oncol Hematol 79: 31-42, 2011
6. Komatsuda A, Masai R, Ohtani H, Togashi M, Maki N, Sawada K, Wakui H: Monoclonal immunoglobulin deposition disease associated with membranous features. Nephrol Dial Transplant 23: 3888-3894, 2008
7. Pozzi C, D'Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, Quattrocchio G, Rollino C, Segagni S, Locatelli F: Light chain deposition disease with renal involvement: Clinical characteristics and prognostic factors. Am J Kidney Dis 42: 1154-1163, 2003
8. Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR: Monoclonal immunoglobulin deposition disease: Light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 112: 455-464, 1990
9. Nasr SH, Galgano SJ, Markowitz GS, Stokes MB, Ďagati VD: Immunofluorescence on pronase-digested paraffin sections: A valuable salvage technique for renal biopsies. Kidney Int 70: 2148-2151, 2006
10. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B: Scientific Advisors of the International Myeloma Foundation: Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4: 379-398, 2003
11. Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, Eladari D: Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammo-pathies. Nephrol Dial Transplant 13: 1438-1445, 1998
12. Gertz MA, Rajkumar SV: Primary systemic amyloidosis. Curr Treat Options Oncol 3: 261-271, 2002
13. Ronco P, Plaisier E, Mougenot B, Aucouturier P: Immunoglobulin light (heavy)-chain deposition disease: From molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 1: 1342-1350, 2006
14. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P: Light chain deposition disease: A model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 12: 1558-1565, 2001
15. Aucouturier P, Khamlichi AA, Touchard G, Justrabo E, Cogne M, Chauffert B, Martin F, Preud'homme JL: Brief report: Heavy-chain deposition disease. N Engl J Med 329: 1389-1393, 1993
16. Hassoun H, Flombaum C, D'Agati VD, Rafferty BT, Cohen A, Klimek VM, Boruchov A, Kewalramani T, Reich L, Nimer SD, Comenzo RL: High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 42: 405-412, 2008
17. Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos MA: Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 94: 300-302, 2009
18. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani MS, Melzi D'Eril GV, Moratti R, Merlini G: Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 55: 499-504, 2009
19. Wan JX, Fukuda N, Endo M, Tahira Y, Yao EH, Matsuda H, Ueno T, Matsumoto K: Complement 3 is involved in changing the phenotype of human glomerular mesangial cells. J Cell Physiol 213: 495-501, 2007
20. Turnberg D, Lewis M, Moss J, Xu Y, Botto M, Cook HT: Complement activation contributes to both glomerular and tubulointerstitial damage in adriamycin nephropathy in mice. J Immunol 177: 4094-4102, 2006
21. Cheng IK, Ho SK, Chan DT, Ng WK, Chan KW: Crescentic nodular glomerulosclerosis secondary to truncated immuno-globulin alpha heavy chain deposition. Am J Kidney Dis 28: 283-288, 1996
22. Strøm EH, Fogazzi GB, Banfi G, Pozzi C, Mihatsch MJ: Light chain deposition disease of the kidney. Morphological aspects in 24 patients. Virchows Arch 425: 271-280, 1994
23. Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N: Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 23: 2052-2057, 2008
24. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Brouet JC, Fermand JP: High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 65: 642-648, 2004